iBio (NYSE:IBIO) (NYSE: IBIO) is a biopharmaceutical and contract development and manufacturing organization that employs proprietary plant-based expression systems to accelerate the discovery, development and production of complex proteins. Its FastPharming platform leverages transient expression in plant hosts to produce vaccines, monoclonal antibodies and therapeutic proteins with shortened development timelines. The company’s ibioCDMO division offers end-to-end services, including cell line engineering, process development, scale-up and fill/finish operations, tailored to both small biotech innovators and established pharmaceutical firms.
Headquartered in Bryan-College Station, Texas, iBio operates a fully integrated cGMP facility that supports activities from preclinical research through commercial manufacturing. The company’s plant-based approach is designed to provide flexible capacity, rapid scale-up and cost-effective production compared with traditional mammalian cell or microbial systems. iBio has applied its technology to infectious disease vaccines, immuno-oncology candidates and specialty biologics, collaborating with partners across North America, Europe and Asia.
Since its founding in 2008, iBio has advanced its proprietary expression and glycosylation enhancement technologies, forging strategic partnerships and in-licensing agreements to broaden its product pipeline. Early milestones included the successful demonstration of large-scale protein expression in plant hosts and the establishment of a dedicated manufacturing campus. Over time, iBio has expanded its capabilities to meet evolving global demand for rapid response vaccine manufacturing and specialized bioprocessing services.
Under the leadership of Chief Executive Officer Robert Kay, a veteran in bioprocess development and biologics manufacturing, iBio continues to invest in platform innovation and facility expansion. The company’s focus on flexible, plant-based production aims to address emergent public health challenges and to support its partners in bringing novel biologics from concept to commercial supply.
